relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   51 Trials   51 Trials   979 News 


«12345678910111213...1314»
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma. (Pubmed Central) -  Oct 22, 2022   
    Nivolumab/relatlimab adds an additional first-line treatment option demonstrating promising improved PFS for patients with unresectable or metastatic melanoma, particularly those with PD-L1 <1% and/or LAG 3 ≥1%. Additional uses of nivolumab/relatlimab may be on the horizon as further clinical trials are ongoing.
  • ||||||||||  Review, Journal:  Advances in novel systemic therapies for advanced hepatocellular carcinoma. (Pubmed Central) -  Oct 21, 2022   
    Treatment options for advanced HCC are limited, with sorafenib representing the only systemic agent approved for treatment of advanced HCC in more than a decade...In particular, combinations of ICIs with antiangiogenic drugs, or with other ICIs, represent one of the most promising strategies. Herein we provide a comprehensive overview of the main therapeutic advances in the systemic treatment of HCC, focusing on the most relevant ongoing clinical trials.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Preclinical, Journal, Combination therapy:  Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. (Pubmed Central) -  Oct 6, 2022   
    In toxicity studies in cynomolgus monkeys, relatlimab was generally well-tolerated when combined with nivolumab. These results are consistent with findings from the RELATIVITY-047 phase II/III trial showing that relatlimab combined with nivolumab is a well-tolerated regimen that demonstrates superior progression-free survival compared with nivolumab monotherapy in patients with unresectable or metastatic melanoma.
  • ||||||||||  INCA32459 / Incyte
    A human bispecific antibody targeting LAG-3 and PD-1 (INCA32459) potently activates exhausted T cells (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1518;    
    Conclusions We have developed INCA32459, a potent dual inhibitor of PD-1 and LAG-3 in preclinical models, which induces activation of exhausted T cells to a greater extent than a combination of bivalent monospecific antibodies targeting PD-1 (nivolumab analog) and LAG-3 (relatlimab analog). These data support the clinical evaluation of INCA32459, and a phase 1 study in cancer patients is underway.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    PD1 and LAG3 synergize on CD8+ T cells to hinder IFNγ-dependent anti-tumor immunity (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1124;    
    Conclusions Overall PD1 and LAG3 limit antitumor immune effects as PD1/LAG3-deficient pMEL AT resulted in reduced tumor growth and enhanced survival due to increased functionality, dependent on IFNγ signaling. These results provide mechanistic insight for the success seen with the clinical development of anti-LAG3 agents in combination with anti-PD1.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA () -  Sep 9, 2022 - Abstract #CTOS2022CTOS_216;    
    The combination was well tolerated and no new safety signals were found in this rare patient population. Correlative studies are ongoing.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdualag (nivolumab/relatlimab) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
    Preclinical, Review, Journal:  Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. (Pubmed Central) -  Aug 22, 2022   
    Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (FDA) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma...We will also summarize results achieved by other LAG-3 targeting molecules with promising anti-tumor activities currently under clinical development in phases I, I/II, II, and III. Opdualag will boost the entry of more LAG-3 targeting molecules into clinical practice, supporting the accumulating evidence highlighting the pivotal role of LAG-3 in cancer.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdualag (nivolumab/relatlimab) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Nivolumab and Relatlimab-rmbw. (Pubmed Central) -  Jun 25, 2022   
    N=77 --> 108 No abstract available
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Nivolumab Plus Relatlimab: First Approval. (Pubmed Central) -  Jun 23, 2022   
    In March 2022, nivolumab plus relatlimab received its first approval in the USA for the treatment of unresectable or metastatic melanoma in adult patients and paediatric patients aged ≥ 12 years who weigh ≥ 40 kg. This article summarizes the milestones in the development of this combination therapy leading to this first approval for unresectable or metastatic melanoma.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. (Pubmed Central) -  Jun 8, 2022   
    Ipilimumab/nivolumab is the first combination of immune checkpoint inhibitors to improve progression-free survival and overall survival in the first-line setting, with durable responses and the longest median overall survival, 72.1 months, of any drug therapy approved for advanced melanoma...More recently, the novel immune checkpoint inhibitor combination of nivolumab/relatlimab (anti-PD-1/anti-LAG3) showed improved progression-free survival compared with nivolumab alone in the first-line setting and was well tolerated; thus, it is likely this combination will be added to the armamentarium as a first-line treatment for advanced melanoma...Intralesional treatments hold promise for accessible metastases, although their broad application in the clinic will be limited. Prognostic and predictive biomarkers, as well as strategies to reduce treatment-related toxicities and overcome resistance, are required and are now the focus of clinical and translational research.